Literature DB >> 7662213

The treatment of microsporidial diarrhoea with thalidomide.

D Sharpstone, A Rowbottom, M Nelson, B Gazzard.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7662213     DOI: 10.1097/00002030-199506000-00025

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


× No keyword cloud information.
  8 in total

1.  Single-dose pharmacokinetics of thalidomide in human immunodeficiency virus-infected patients.

Authors:  S C Piscitelli; W D Figg; B Hahn; G Kelly; S Thomas; R E Walker
Journal:  Antimicrob Agents Chemother       Date:  1997-12       Impact factor: 5.191

2.  Small intestinal transit, absorption, and permeability in patients with AIDS with and without diarrhoea.

Authors:  D Sharpstone; P Neild; R Crane; C Taylor; C Hodgson; R Sherwood; B Gazzard; I Bjarnason
Journal:  Gut       Date:  1999-07       Impact factor: 23.059

Review 3.  Molecular techniques for detection, species differentiation, and phylogenetic analysis of microsporidia.

Authors:  C Franzen; A Müller
Journal:  Clin Microbiol Rev       Date:  1999-04       Impact factor: 26.132

Review 4.  Lack of in vitro antimicrosporidian activity of thalidomide.

Authors:  O Ridoux; M Drancourt
Journal:  Antimicrob Agents Chemother       Date:  1999-09       Impact factor: 5.191

5.  Effects of thalidomide on intracellular Mycobacterium leprae in normal and activated macrophages.

Authors:  A Tadesse; E J Shannon
Journal:  Clin Diagn Lab Immunol       Date:  2005-01

6.  Systemic Injection of Thalidomide Prevent and Attenuate Neuropathic Pain and Alleviate Neuroinflammatory Response in the Spinal Dorsal Horn.

Authors:  Hao Xu; Sha-Jie Dang; Yuan-Yuan Cui; Zhen-Yu Wu; Jun-Feng Zhang; Xiao-Peng Mei; Yu-Peng Feng; Yun-Qing Li
Journal:  J Pain Res       Date:  2019-11-29       Impact factor: 3.133

Review 7.  Gastrointestinal manifestations of HIV infection.

Authors:  D Sharpstone; B Gazzard
Journal:  Lancet       Date:  1996-08-10       Impact factor: 79.321

8.  Phase I study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers.

Authors:  J B Bartlett; A Michael; I A Clarke; K Dredge; S Nicholson; H Kristeleit; A Polychronis; H Pandha; G W Muller; D I Stirling; J Zeldis; A G Dalgleish
Journal:  Br J Cancer       Date:  2004-03-08       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.